iPS Cells & Regenerative Medicine– category –
-
iPS Cells & Regenerative Medicine Weekly Report July 12, 2026
📄 Weekly Report July 12, 2026 (PDF) — Download Weekly Report July 12, 2026 (PDF) — DownloadDownload 🎙 Podcast July 12, 2026 (MP3) — Play & Download iPS_RegenerativeMedicineEnglishPodcast_20260712.mp3Download -
Vector BioMed Proposes Platform to Accelerate CAR-T Therapy Development from Gene Sequence to Clinic-Ready in Under 12 Months
Vector BioMed USA Overview Vector BioMed is advocating for a platform capable of accelerating CAR-T therapy development from gene sequencing to clinic-ready in under 12 months. This platform aims to reduce therapy costs by adopting a tra... -
Cellistic Unveils Specialized CDMO Services for iPSC-Derived Cell Therapies, Expediting Development from Early Stages to GMP
Cellistic Belgium Overview Cellistic is offering specialized Contract Development and Manufacturing Organization (CDMO) services tailored for iPSC-derived cell therapies. Leveraging bioreactor-based, GMP-compliant processes, the company ... -
Taiwan’s ITRI Establishes Highly Stable iPSC-Based MSC and Exosome Manufacturing Platform to Advance Regenerative Medicine
Industrial Technology Research Institute (ITRI) Taiwan Overview Taiwan's Industrial Technology Research Institute (ITRI) has established a highly stable iPSC-based mesenchymal stem cell (MSC) and exosome manufacturing platform. This plat... -
Imunopharm Files for Shanghai STAR Market IPO, Targeting $550 Million Valuation to Expand CAR-T and CDMO Business
VCBeat China Overview Chinese biotechnology firm Imunopharm has filed for an Initial Public Offering (IPO) on the Shanghai STAR Market, targeting a valuation of 4 billion RMB (approximately $550 million). The company's pipeline includes ... -
ICR Unveils New ‘DOSET’ Statistical Approach to Optimize Early-Stage Cancer Clinical Trials for CAR-T and Advanced Therapies
The Institute of Cancer Research, London UK Overview Researchers at The Institute of Cancer Research (ICR), London, have developed 'DOSET' (Dose Optimization with Simultaneous Efficacy and Toxicity), a new statistical approach to identif... -
Hospital Capacity, Not Just Manufacturing, Identified as True Bottleneck for CAR-T Therapy Commercialization
Chivanta Unknown Overview The greatest challenge in commercializing CAR-T cell therapies is not solely manufacturing capacity but also the hospital infrastructure and the overall treatment process. Clinical operational bottlenecks, speci... -
Porton Advanced’s UC-MSC Cell Bank for Exosome Manufacturing Receives FDA Drug Master File (DMF) Acceptance
Morningstar USA Overview Porton Advanced, a CDMO, announced that its umbilical cord-derived mesenchymal stem cell (UC-MSC) cell bank for exosome manufacturing has received Drug Master File (DMF) acceptance from the U.S. FDA. This accepta... -
Fate Therapeutics to Announce Preliminary Clinical Data for iPSC-Derived CAR T-Cell FT819 for Systemic Sclerosis at ISSCR 2026
GlobeNewswire USA Overview Fate Therapeutics announced it will present preliminary clinical data for its iPSC-derived 'off-the-shelf' CAR T-cell candidate FT819 for systemic sclerosis (SSc) at the International Society for Stem Cell Rese... -
Scribe Therapeutics Files for Nasdaq IPO, Advancing CRISPR-Based Cardiovascular Disease Platform STX-1150 for Hypercholesterolemia
Endpoints News USA Overview Scribe Therapeutics, co-founded by Nobel laureate Dr. Jennifer Doudna, has filed for an initial public offering (IPO) on Nasdaq. This move signals a crucial strategy for the company to expand its CRISPR-based ...
